Dietary consumption has recently been identified as a major environmental source of pro-inflammatory advanced glycation end-products (AGEs) in humans. It is disputed whether dietary AGEs represent a risk to human health. Nε-(carboxymethyl)lysine (CML), a representative AGE compound found in food, has been suggested to make a significant contribution to circulating CML levels. However, recent studies have found that the dietary intake of AGEs is not associated with plasma CML concentrations. We have shown that the serum levels of glyceraldehyde-derived AGEs (Glycer-AGEs), but not hemoglobin A1c, glucose-derived AGEs (Glu-AGEs), or CML, could be used as biomarkers for predicting the progression of atherosclerosis and future cardiovascular events. We also detected the production/accumulation of Glycer-AGEs in normal rats administered Glu-AGE-rich beverages. Therefore, we assessed the concentrations of various AGEs in a total of 1,650 beverages and foods that are commonly consumed in Japan. The concentrations of four kinds of AGEs (Glu-AGEs, fructose-derived AGEs (Fru-AGEs), CML, and Glycer-AGEs) were measured with competitive enzyme-linked immunosorbent assays involving immunoaffinity-purified specific antibodies. The results of the latter assays indicated that Glu-AGEs and Fru-AGEs (especially Glu-AGEs), but not CML or Glycer-AGEs, are present at appreciable levels in beverages and foods that are commonly consumed by Japanese. Glu-AGEs, Fru-AGEs, CML, and Glycer-AGEs exhibited concentrations of ≥85%, 2–12%, <3%, and trace amounts in the examined beverages and ≥82%, 5–15%, <3%, and trace amounts in the tested foods, respectively. The results of the present study indicate that some lactic acid bacteria beverages, carbonated drinks, sugar-sweetened fruit drinks, sports drinks, mixed fruit juices, confectionery (snacks), dried fruits, cakes, cereals, and prepared foods contain markedly higher Glu-AGE levels than other classes of beverages and foods. We provide useful data on the concentrations of various AGEs, especially Glu-AGEs, in commonly consumed beverages and foods.
Citation: Takeuchi M, Takino J-i, Furuno S, Shirai H, Kawakami M, Muramatsu M, et al. (2015) Assessment of the Concentrations of Various Advanced Glycation End-Products in Beverages and Foods That Are Commonly Consumed in Japan. PLoS ONE 10(3): e0118652. https://doi.org/10.1371/journal.pone.0118652
Academic Editor: Barry I. Hudson, University of Miami, UNITED STATES
Received: July 10, 2014; Accepted: January 9, 2015; Published: March 2, 2015
Copyright: © 2015 Takeuchi et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited
Data Availability: All relevant data are within the paper.
Funding: This study was supported by grants from the Japan Society for the Promotion of Science (JSPS, KAKENHI Grant Numbers 19300254, 22300264, & 25282029 for MT). The funders had no role in the study design, data collection or analysis, the decision to publish, or the preparation of the manuscript.
Competing interests: The authors declare that no competing interests exist.
In humans, two major sources of advanced glycation end-products (AGEs) have been identified, exogenous and endogenous AGEs [1–5]. AGEs are formed by the Maillard reaction, a non-enzymatic reaction between the aldehyde or ketone groups of reducing sugars, such as glucose, fructose, and glyceraldehyde, and the terminal α-amino groups or ε-amino groups of protein lysine residues [2–5]. AGEs were originally characterized by their yellow-brown fluorescent color and their ability to form cross-links with and between amino groups; however, the term is now used for a broad range of advanced products of the glycation process, including Nε-(carboxymethyl)lysine (CML), Nε-(carboxyethyl)lysine (CEL), and pyrraline, which are colorless, do not fluoresce, and do not form cross-links with proteins [1–5]. The use of CML as a marker of AGE formation in food has recently led to the development of a database containing the CML concentrations of 549 foodstuffs [6,7]. However, the inconsistencies between the information in this database and data obtained with other methods highlight the considerable challenges associated with analyzing AGEs . Moreover, dietary CML might pose a risk to human health, as it enhances oxidative stress and initiates inflammatory responses, which ultimately lead to atherosclerosis [9,10]. While previous studies have suggested that dietary CML makes a significant contribution to in vivo CML concentrations , two recent studies have reported that this is not true for humans  or rats . Semba et al. suggested that the excessive consumption of foods considered to be high in AGEs might not have a major effect on serum CML concentrations .
We previously demonstrated that glucose, fructose, α-hydroxyaldehydes (glyceraldehyde and glycolaldehyde), and dicarbonyl compounds (glyoxal (GO), methylglyoxal (MGO), and 3-deoxyglucosone (3-DG)) were actively involved in protein glycation [13–16]. Seven immunochemically distinct classes of AGEs (glucose-derived AGEs, Glu-AGEs; fructose-derived AGEs, Fru-AGEs; glyceraldehyde-derived AGEs, Glycer-AGEs; glycolaldehyde-derived AGEs, Glycol-AGEs; GO-derived AGEs, GO-AGEs; MGO-derived AGEs, MGO-AGEs; and 3-DG-derived AGEs, 3-DG-AGEs) have been detected in the sera of type 2 diabetic patients on hemodialysis [13–16]. Based on these findings, we proposed an in vivo pathway for the formation of distinct AGEs involving the Maillard reaction, sugar autoxidation, and sugar metabolic pathways, as shown in Fig. 1.
Reducing sugars, such as glucose, fructose, and glyceraldehyde, are known to react non-enzymatically with the amino groups of proteins to form reversible Schiff bases and Amadori/Heyns products. These early glycation products undergo further complex reactions such as rearrangement, dehydration, and condensation to become irreversibly cross-linked heterogeneous fluorescent derivatives, termed AGEs. Glu-AGEs, glucose-derived AGEs; Fru-AGEs, fructose-derived AGEs; Glycer-AGEs, glyceraldehyde-derived AGEs; Glycol-AGEs, glycolaldehyde-derived AGEs; MGO-AGEs, methylglyoxal-derived AGEs; GO-AGEs, glyoxal-derived AGEs; 3-DG-AGEs, 3-deoxyglucosone-derived AGEs; CML, Nε-(carboxymethyl)lysine; P-NH2, free amino residue of protein; GOLD, GO-lysine dimer; GA-pyridine, 3-hydroxy-4-hydroxymethyl-1-(5-carboxypentyl) pyridinium cation; DOLD, 3-DG-lysine dimer; CEL, Nε-(carboxyethyl)lysine; MOLD, MGO-lysine dimer; GLAP, glyceraldehyde-derived pyridinium compound.
We recently demonstrated that interactions between Glycer-AGEs and the receptor for AGEs (RAGE) affect intracellular signaling, gene expression, and the release of pro-inflammatory molecules and also induce oxidative stress in numerous types of cells, all of which can contribute to the pathological changes observed in various chronic diseases [17–19]. Furthermore, we detected increased hepatic RAGE expression and the enhanced production/accumulation of Glycer-AGEs in normal rats administered Glu-AGE-rich beverages . These findings indicate that Glu-AGEs, which are frequently found in beverages and foods, and hence, are taken into the body orally, enhance the production/accumulation of Glycer-AGEs, leading to Glycer-AGE-RAGE interactions. Our recent studies indicated that the serum levels of Glycer-AGEs, but not hemoglobin A1c (HbA1c), Glu-AGEs, or CML, could be used as biomarkers for predicting the progression of lifestyle-related diseases [21–25]. We previously demonstrated that the enhanced production/accumulation of Glycer-AGEs after the oral consumption of Glu-AGEs plays an important role in the pathogenesis of vascular damage .
Therefore, the objective of the present study was to assess the concentrations of four kinds of AGEs; i.e., Glu-AGEs, Fru-AGEs, CML, and Glycer-AGEs, which have been detected in the sera of both non-diabetic and diabetic subjects [13–16,21–26], in beverages and foods that are commonly consumed in Japan.
Materials and Methods
Preparation of various advanced glycation end-products (AGEs)
Glu-AGEs, Fru-AGEs, Glycer-AGEs, and CML proteins were prepared as described in previous studies [13–16]. Briefly, 25 mg/ml rabbit serum albumin (RSA, A0764, Sigma-Aldrich, St Louis, MO, USA) or bovine serum albumin (BSA, A0281, Sigma-Aldrich) were incubated under sterile conditions with 0.5 M D-glucose, D-fructose, or 0.1 M DL-glyceraldehyde and 5 mM diethylenetriaminepentaacetic acid (Dojindo Laboratories, Kumamoto, Japan) in 0.2 M phosphate buffer (pH 7.4) at 37°C for 8 weeks (or 7 days for the samples incubated with glyceraldehyde). Low molecular weight (LMW) reactants and the glucose, fructose, or glyceraldehyde were removed using a PD-10 chromatography column (GE Healthcare UK, Buckinghamshire, UK) and dialysis against phosphate buffered saline (PBS). CML-RSA, CML-BSA, CML-human serum albumin (HSA), CML-hemoglobin (Hb), and CML-ribonuclease A (RNase A) were prepared as described previously . Briefly, 50 mg/ml each of RSA, BSA, HSA, Hb, and RNase A were incubated at 37°C for 24 h with 50 mM glyoxylic acid and 150 mM sodium cyanoborohydride in 0.2 M phosphate buffer (pH 7.4), before being subjected to PD-10 column chromatography and dialysis against PBS. Protein concentrations were determined with the DC protein assay reagent (Bio-Rad Laboratories, Richmond, CA, USA) using BSA as a standard.
Preparation of AGE-specific antibodies
Four kinds of immunoaffinity-purified antibodies were prepared as described in previous studies [13–16]. Briefly, 4 mg of three types of AGE-RSA (incubated with glucose, fructose, or glyceraldehyde) were emulsified in 50% Freund’s complete adjuvant (Wako Pure Chemical Industries, Osaka, Japan) and then injected intradermally into Japanese white rabbits (Sankyo Labo Service Corporation, Tokyo, Japan). This procedure was repeated at weekly intervals for 6 weeks. After a 2-week break, the rabbits were given a booster injection of 4 mg of the appropriate antigen. The animals were bled on the 10th day after the last injection, and their sera were obtained for further affinity purification. CNBr-activated Sepharose 4B gels (GE Healthcare UK) were coupled to Glu-AGE-BSA, Fru-AGE-BSA, Glycer-AGE-BSA, or CML-BSA, as described previously [13–16]. The anti-Glu-AGE antiserum, which contained anti-Glu-AGE and anti-CML antibodies, was applied to a column (2.5 x 5.5 cm) containing Sepharose 4B coupled to Glu-AGE-BSA. After extensive washing with PBS, the adsorbed fractions were eluted with 20 mM sodium phosphate buffer containing 1 M potassium thiocyanate (pH 7.4) (elution buffer). The eluted fractions were pooled, concentrated using Centriprep-10 (Millipore Corporation, Billerica, MA, USA), and passed through a PD-10 column equilibrated with PBS. The eluted fraction was then loaded onto a column (1.5 x 5.5 cm) containing Sepharose 4B coupled with CML-BSA, which was washed with PBS to obtain the unadsorbed fraction (anti-Glu-AGE antibody). The adsorbed fraction (anti-CML antibody) was then eluted with elution buffer. The anti-Glu-AGE and anti-CML antibodies were pooled (separately), concentrated with Centriprep-10, and passed through a PD-10 column equilibrated with PBS, before being used in this study [13,15]. The anti-Fru-AGE or anti-Glycer-AGE antisera were applied to columns containing Sepharose 4B coupled to Fru-AGE- or Glycer-AGE-BSA. After extensive washing with PBS, the adsorbed fractions were eluted with elution buffer. Each of the eluted fractions was pooled, concentrated using Centriprep-10, and passed through a PD-10 column equilibrated with PBS. Then, they were loaded onto a column containing Sepharose 4B coupled to CML-BSA, which was washed with PBS to obtain the unadsorbed fraction (anti-Fru-AGE or anti-Glycer-AGE antibodies). The anti-Fru-AGE and anti-Glycer-AGE antibodies were pooled (separately), concentrated with Centriprep-10, and passed through a PD-10 column equilibrated with PBS and then used in this study [14,16].
The immunoaffinity-purified anti-Glu-AGE antibody did not recognize well-characterized AGE structures, such as CML, CEL, pyrraline, pentosidine, argpyrimidine, imidazolone, GO-lysine dimers (GOLD), and MGO-lysine dimers (MOLD). In addition, it did not recognize AGEs whose structures remain unknown, such as Fru-AGEs, Glycer-AGEs, Glycol-AGEs, GO-AGEs, MGO-AGEs, and 3-DG-AGEs [13,15,27]. Instead, the anti-Glu-AGE antibody specifically recognized unique unknown Glu-AGE structures. The immunoaffinity-purified anti-Fru-AGE antibody did not recognize well-characterized AGE structures, such as CML, CEL, pyrraline, pentosidine, and argpyrimidine. In addition, it did not recognize AGE whose structures remain unknown, such as Glu-AGEs, Glycer-AGEs, Glycol-AGEs, GO-AGEs, MGO-AGEs, and 3-DG-AGEs . Instead, the anti-Fru-AGE antibody specifically recognized unique unknown Fru-AGE structures. The immunoaffinity-purified anti-Glycer-AGE antibody did not recognize well-characterized AGE structures, such as CML, CEL, pyrraline, pentosidine, argpyrimidine, imidazolone, GOLD, MOLD, and glyceraldehyde-derived pyridinium (GLAP). Furthermore, it did not recognize AGE whose structures are unknown, such as Glu-AGEs, Fru-AGEs, Glycol-AGEs, GO-AGEs, MGO-AGEs, and 3-DG-AGEs [14,23]. Instead, the anti-Glycer-AGE antibody specifically recognized unique unknown Glycer-AGE structures. The three types of AGE antibodies were able to detect both high-molecular weight (HMW) and LMW Glu-AGEs, Fru-AGEs, or Glycer-AGEs with unique unknown structures in serum [13–16,21–26]. On the other hand, the immunoaffinity-purified anti-CML antibody recognized a common epitope that is shared by protein-bound CML (such as CML-RSA, CML-BSA, CML-HSA, CML-Hb, and CML-RNase A) and free CML molecules, whereas it did not react with lysine, Amadori products (glycated HSA), unmodified proteins, pentosidine, pyrraline, argpyrimidine, imidazolone, or CEL . The anti-CML antibody was able to detect both HMW and LMW CML structures in serum .
Competitive enzyme-linked immunosorbent assay (ELISA)
The concentrations of four kinds of AGEs (Glu-AGEs, Fru-AGEs, CML, and Glycer-AGEs) were measured with competitive ELISA using the immunoaffinity-purified antibodies described above. Briefly, a 96-well (flat bottomed without a lid, high binding) enzyme immunoassay /radioimmunoassay plate (Corning Incorporated, Corning, NY, USA) was coated with 1 μg/ml of Glu-AGE-BSA, Fru-AGE-BSA, CML-BSA, or Glycer-AGE-BSA standard solution and incubated overnight at 4°C. The wells were washed three times with 0.3 ml of the washing solution (PBS containing 0.05% Tween-20), before being blocked via incubation for 1 h with 0.2 ml of a PBS solution containing 1% BSA. After the wells had been washed with the washing solution, test samples (50 μl) were added to each well as competitors for 50 μl of immunoaffinity-purified anti-Glu-AGE, anti-Fru-AGE, anti-CML, or anti-Glycer-AGE antibodies (1:1000~1:2500 dilution), and then the plates were incubated for 2 h at room temperature under gentle shaking in a horizontal rotary shaker (EYELA, MMS-1, Tokyo, Japan). The wells were then washed with washing solution and developed with an alkaline phosphatase-conjugated sheep anti-rabbit IgG (Millipore Corporation, Billerica, MA, USA) using p-nitrophenyl phosphate as the colorimetric substrate (Pierce, Rockford, IL, USA). The AGE concentrations of each sample were read from the calibration curves for Glu-AGE-BSA, Fru-AGE-BSA, CML-BSA, or Glycer-AGE-BSA standards and were expressed as Glu-AGE, Fru-AGE, CML, or Glycer-AGE units (U) per ml, where 1U corresponded to 1 μg of the Glu-AGE-BSA, Fru-AGE-BSA, CML-BSA, or Glycer-AGE-BSA standard [13–16].
Assessment of the concentrations of various AGEs
Commonly consumed beverages and foods were obtained from vending machines, convenience stores, supermarkets, fast food stores (including doughnut or hamburger stores), bento-ya (shops that sell lunch sets), or family restaurants. Samples of beverages and liquefied foods (mainly seasonings) were analyzed using competitive ELISA after they had been diluted. To prepare food samples for the AGE measurements, solid food was first crushed uniformly with a food processor (Cuisinart, Mini-Prep Processor/Little Pro Plus, Tokyo, Japan). In the case of the bento-ya/convenience store lunch boxes, any fish, meat, vegetables (including nimono/aemono), seasonings and spices, and rice within them were examined separately, whereas for hamburgers, any meat/fish, vegetables, sauce, and bread/rice were examined separately. We then weighed out 5 g of the uniformly crushed food, added 45 ml of the sample dilution buffer (Tris/HCl buffer containing 0.05% Tween-20, pH 7.4), and homogenized it for 1 min at 15,000 rpm using an Ace Homogenizer (Nippon Seiki Co., Ltd., Nagaoka, Japan). The homogenate was rotated with a tube rotator (AS ONE, AM-9, Osaka, Japan) for 3 h at room temperature. After being centrifuged for 20 min at 3,500 rpm at 4°C, the supernatant was used for the assessments of AGE levels. We purchased at least 2 of each beverage and food, and prepared at least 2 samples of each product for AGE measurement. The concentrations of the four abovementioned types of AGEs in each beverage or food extract were measured using competitive ELISA after the extract had been diluted 10- to 100,000-fold (after controlling for dilution) with sample dilution buffer. The AGE concentrations of each beverage and food item are shown as mean values of at least three measurements per sample and are expressed as AGE units (U). The tests for the four kinds of AGEs displayed sensitivity values of 0.1 U/ml. In the case of the bento-ya/convenience store lunch boxes, the AGE concentrations of any fish, meat, vegetables (including nimono/aemono), seasonings and spices, and rice were combined and expressed as mean units per meal/lunch box. For hamburgers, the AGE concentrations of any meat/fish, vegetables, sauce, and bread/rice were combined and expressed as mean units per hamburger. The concentrations of the four kinds of AGEs were calculated based on standard serving sizes (65~500 ml/bottle) for beverages or on the standard serving sizes consumed by average Japanese people for foods (e.g., one bag/box of confectionery, one bag/box of prepared foods, 15 (~150 for noodle tsuyu) g/ml seasonings and spices, one hamburger, and one convenience store lunch box).
Assessment of the AGE concentrations of common beverages as determined by their AGE levels
We classified beverages according to the Japanese Agricultural Standard (JAS). The concentrations of the four kinds of AGEs in each type of beverage are shown in Fig. 2. Glu-AGEs, Fru-AGEs, CML, and Glycer-AGEs exhibited concentrations of ≥85%, 2–12%, <3%, and trace amounts, respectively. Table 1 shows a list of commonly consumed beverages that exhibited Glu-AGE concentrations of ≥100,000 U/bottle. The highest Glu-AGE concentrations were detected in the lactic acid bacteria beverages Pil∙Cres (two types; 264,090 and 240,870 U/65 ml bottle), Yakult (eight types; max: 243,890—min: 60,900 U/65 or 80 ml bottle), and lactic acid bacteria Power Peach (171,320 U/250 ml bottle). The lactic acid bacteria beverages containing large amounts of Glu-AGEs were all produced via processes in which high-fructose corn syrup (HFCS) and skimmed milk were mixed and reacted at high temperature, which would have altered the mixture’s Glu-AGE levels, before the seeding and culturing of lactic acid bacteria. On the other hand, the lactic acid bacteria beverages that had been colored using caramel had low levels of Glu-AGEs. Moreover, beverages that contained artificial sweeteners and carbonated drinks displayed low levels of Glu-AGEs. Tea, black coffee, and oolong tea did not contain many Glu-AGEs. The numbers of beverages in each category that contained ≥100,000; 50,000–99,999; 20,000–49,999; and <20,000 U/bottle of Glu-AGEs are shown in Table 2. The concentration of Glu-AGEs was ≥20,000 U/bottle in ca. 45% of the beverages examined.
Beverages were classified according to the Japanese Agricultural Standard (JAS). The mean concentrations of four kinds of AGEs (Glu-AGEs, Fru-AGEs, CML, and Glycer-AGEs) in each beverage are expressed as AGE units (U) per bottle and are based on the standard serving size (65~500 ml/bottle) of each product in Japan.
Assessment of the AGE concentrations of common foods as determined by their AGE levels
We classified the foods according to the Standard Tables of Food Composition in Japan (5th revised and enlarged edition, 2009). The concentrations of the four kinds of AGEs were measured in over 750 commercially available foods based on the standard servings consumed by average Japanese people. The concentrations of the four kinds of AGEs in each type of food are shown in Fig. 3. Glu-AGEs, Fru-AGEs, CML, and Glycer-AGEs exhibited concentrations of ≥82%, 5–15%, <3%, and trace amounts, respectively. Commonly consumed foods that demonstrated Glu-AGE levels of ≥100,000 U/meal are shown in Table 3. The highest Glu-AGE levels in the small food group were detected in snacks that had been prepared via dry-heat processing. These products contained high levels of Glu-AGEs because the processes used to produce them involved the heating of raw materials containing large amounts of reducing sugars (such as HFCS and dried fruit) and soybean flour or flour (which contain large quantities of lysine) at a high temperature for a long period of time. On the other hand, prepared foods such as bentos containing many vegetables and broiled fish contained low levels of Glu-AGEs. Moreover, the algae, vegetables, and pulses did not contain high levels of Glu-AGEs. The numbers of foods in each category that contained ≥100,000; 50,000–99,999; 20,000–49,999; and <20,000 U/meal of Glu-AGEs are shown in Table 4. Approximately 23% of the foods examined contained ≥20,000 U of Glu-AGEs per meal.
Food items were classified according to the Standard Tables of Food Composition (5th revised and enlarged edition, 2009). The mean concentrations of four kinds of AGEs (Glu-AGEs, Fru-AGEs, CML, and Glycer-AGEs) in each food item are expressed as AGE units (U) per meal and are based on the standard servings consumed by average individuals in Japan.
A previous study indicated that a significant proportion of pro-inflammatory AGEs are derived from dietary components ; however, it is disputed whether such AGEs are a health risk [8,28–30]. ELISA or liquid chromatography-mass spectrometry (LC-MS) are usually used to assess the levels of AGEs in bodily secretions, foods, and beverages. However, it is not possible to assess the levels of both HMW- and LMW-AGEs using any of the current approaches. Subjecting foods to heating results in the formation of various AGE molecules, with the types of AGEs produced depending on the heat treatment method employed and the food involved. Unfortunately, most previous studies only examined the levels of a small number of AGE molecules because of methodological issues [31,32]. The majority of studies of AGEs have focused on representative molecules, particularly CML. Based on assessments of CML levels obtained with ELISA, a database of food products and their AGE concentrations has been produced [6,7]. Foods containing elevated levels of protein and fat, meat substitutes, and processed meats were found to display markedly increased AGE concentrations. However, discrepancies have been detected between the information in the abovementioned database and the data obtained using other approaches, which indicates that more accurate methods for analyzing AGE levels are required . As AGEs are produced when food is heated, eating processed foods, which are subjected to high temperatures during their production, results in greater exposure to AGEs. The Maillard reaction, in which sugar groups react with proteins (which causes foods to turn brown) and cross-links form between proteins, is responsible for AGE synthesis during the heating of foodstuffs . Conversely, CML is colorless and does not promote protein cross-linking or fluoresce [2–5].
There are no established methods for evaluating the serum concentrations of AGEs. Whilst most studies of AGEs have examined CML levels, the role played by CML in pathological conditions is poorly understood. Although numerous other AGE structures are known to exist, little is known about which AGEs make significant contributions to disease. In previous studies, we found that the serum concentrations of Glycer-AGEs, but not those of Glu-AGEs, CML, or HbA1c, could be useful biomarkers for predicting the development of cardiovascular events and atherosclerosis [21–25]. Hence, in the present study we subjected a range of foods and beverages that are commonly consumed in Japan to testing in order to determine their AGE concentrations (their CML, Glu-AGE, Glycer-AGE, and Fru-AGE concentrations). The present study indicates that CML is not a suitable biomarker of dietary AGE consumption (Figs. 2 and 3 and Tables 1 and 3). The findings of the present study indicate that people should not consume excessive amounts of particular types of food such as cereals, dried fruits, seasonings, prepared foods, and confectionery (snacks) or certain beverages, particularly sugar-sweetened fruit drinks, lactic acid bacteria beverages, mixed fruit juices, sports drinks, and carbonated drinks.
Interestingly, the present study demonstrated that a markedly greater number of foods and beverages contain Glu-AGEs than Fru-AGEs, even among dried fruit products and fruit juices, which contain large amounts of fructose. During glycation, the initial kinetics of the reaction are affected by the protein involved, the temperature at which the reaction occurs, the concentration of the reducing sugar, and the percentage of the reducing sugar that possesses an open-chain structure. Compared with glucose, a greater proportion of fructose exhibits an open-chain structure. Studies of glycation have found that the initial rates of fructose-adduct formation are increased in Hb; however, glucose and fructose display similar levels of reactivity with RNase A, and glucose reacts with albumin 8 times more readily than fructose. The discrepancies between these findings might be due to differences in the local conditions at the reaction sites . A Japanese study examined the amounts of glucose and fructose in various fruits. As a result, it was found that the levels of glucose and fructose in 100 g of fruit were as follows: 1.5 g and 1.5 g, respectively, in oranges; 3.0 g and 5.5 g, respectively, in apples; 7.5 g and 8.0 g, respectively, in grapes; and 4.0 g and 2.5 g, respectively, in bananas. Therefore, the detection of Glu-AGEs in fruit seems reasonable, although they contain even more Fru-AGEs. Irrespective of the proteins involved, AGEs are defined as molecules that contain AGE structures. It has been demonstrated that Glu-AGE structures often develop in casein that has reacted with glucose as well as in RNase A, Hb, and albumin. In the present study, the IC50 values of three types of AGE-BSA or CML-BSA standards were found to range from 1.0–1.5 U/mL in competition experiments involving an anti-CML antibody and three anti-AGE antibodies (data not shown); therefore, it is considered that all three anti-AGE antibodies and the anti-CML antibody had similar ability to recognize AGEs in beverages and foods.
When assessing the levels of AGEs using ELISA, it is essential to be aware of the cross-reactivity of the antibodies employed. Detailed assessments of the relevant epitopes are necessary to ensure this, together with precise knowledge of the target structure. In addition, it is necessary to validate the ELISA in each matrix, e.g., using spiking, as the local chemical milieu can affect antigen-antibody binding . At present, our knowledge of the various complex pathways involved in AGE synthesis is insufficient. As AGE synthesis pathways are complex and exhibit a great degree of diversity, a large number of molecules are defined as AGEs. A significant number of dietary AGEs, including argpyrimidine, CEL, pentosidine, imidazolones, CML, pyrraline, GOLD, DOLD, and MOLD, etc., have been detected in vivo [35,36]. In previous studies, we have found that anti-Fru-AGE, anti-Glycer-AGE, and anti-Glu-AGE antibodies recognize epitopes that differ from previously described AGE structures [13–16,23,27]; i.e., it is suggested that these AGE antibodies recognize novel AGE structures.
In humans, it has been demonstrated that roughly 10% of the AGEs in foods and beverages are taken up into the body. Of these, ~33% are excreted in urine within 48 h of their consumption, while ~67% accumulate within the body . In a study conducted in the USA, Semba et al. stated that adults exhibit median (25th/75th percentile) serum CML concentrations of 0.69 (0.60/0.80) μg/ml . In addition, non-diabetic individuals with normal renal function were found to have a mean serum Glu-AGE level of 10.5±1.3 U (one unit equals 1 μg of Glu-AGE-BSA)/ml, whereas diabetic patients and diabetic patients on hemodialysis exhibited serum Glu-AGE concentrations that were >2 times greater (24.7±2.4 U/ml) and ~8 times greater (79.4±9.9 U/ml), respectively, than those seen in the non-diabetic subjects . We examined the serum Glu-AGE levels of healthy subjects and Japanese diabetic nephropathy patients and found that they were 10–20 U/ml and 30–50 U/ml, respectively. The consumption of 100,000 U of dietary Glu-AGEs results in a blood Glu-AGE level of ~2.0 U/ml [100,000 (U) × 0.1 (the proportion that is absorbed) x 1/5,000 (ml of blood)]. The dietary intake of food products containing <20,000 U Glu-AGEs has little effect on the body. On the other hand, care should be taken when mixing Glu-AGE-containing products or consuming large amounts of Glu-AGE-containing beverages or foods as this can result in elevated concentrations of Glu-AGEs and sugar in the blood and promote the hepatic build-up of Glu-AGEs [20,26].
In a previous study, we detected elevated hepatic RAGE expression in normal rats that had been given a Glu-AGE-rich beverage (Yakult) . In addition, the rats’ hepatic cells were found to contain Glycer-AGEs and Glu-AGEs, despite the fact that the beverage administered to the rats did not contain Glycer-AGEs. The above findings suggest that the synthesis and hepatic accumulation of Glycer-AGEs are promoted by Glu-AGEs, which are often found in foods and beverages, resulting in increased Glycer-AGE-RAGE binding [20,26]. In another study, AST-120 (Kremezin, Kureha-Chemical Co., Tokyo, Japan), an oral adsorbent that slows the development of chronic renal failure (CRF) by promoting the removal of uremic toxins, reduced the serum Glu-AGE and Glycer-AGE concentrations of non-diabetic CRF patients . In addition, in an examination of the expression profiles of endothelial cells extracted from the latter patients’ serum samples the mRNA expression levels of monocyte chemoattractant protein-1, vascular cell adhesion molecule-1, and RAGE were found to be significantly downregulated in the cells acquired after AST-120 (Kremezin) treatment compared with those seen in the endothelial cells obtained prior to treatment . The latter results indicated that the consumption of Glu-AGEs might contribute to the development of vascular damage in pathological conditions linked to Glycer-AGE-RAGE interactions. Furthermore, they suggest that reducing the absorption of dietary Glu-AGEs might be a useful strategy for treating lifestyle-related conditions. Further clinical studies might help to elucidate whether lifestyle-related conditions can be prevented by encouraging people to reduce their consumption of Glu-AGEs.
In conclusion, we have presented useful information regarding the AGE concentrations of numerous beverages and foods that are commonly consumed in Japan. As dietary AGEs are derived from numerous precursors, they include a broad range of compounds with different structures and molecular weights. There is insufficient detailed data about the functions and molecular structures of AGEs. Furthermore, little is known about the in vivo activity of AGEs or about their bioavailability and absorption. This is partly because of a dearth of accurate analytical techniques for assessing the concentrations of AGEs in food and tissues. The structures of the epitopes recognized by anti-Fru-AGE, anti-Glycer-AGE, and anti-Glu-AGE antibodies were not examined in the present study; however, we were able to determine that they differ from those of well-defined AGEs as well as those of AGEs derived from carbonyl or sugar molecules with unknown structures. Accordingly, it is possible that Glycer-AGEs, Fru-AGEs, and Glu-AGEs have unique structures, but studies involving spectroscopic and biochemical analyses are required to confirm this.
Conceived and designed the experiments: MT SY. Performed the experiments: MT JT SF HS MK MM YK. Analyzed the data: MT JT. Contributed reagents/materials/analysis tools: MT JT. Wrote the paper: MT.
- 1. Monnier VM, Cerami A. Non-enzymatic browning in vivo: possible process for aging of long-lived proteins. Science. 1981;211: 491–493. pmid:6779377
- 2. Bucala R, Cerami A. Advanced glycosylation: chemistry, biology, and implications for diabetes and aging. Adv Pharmacol. 1992;23: 1–34. pmid:1540533
- 3. Vlassara H, Bucala R, Striker L. Pathogenic effects of advanced glycosylation: biochemical, biologic, and clinical implications for diabetes and aging. Lab Invest. 1994;70: 138–151. pmid:8139257
- 4. Brownlee M. Advanced protein glycosylation in diabetes and aging. Ann Rev Med. 1995;46: 223–234. pmid:7598459
- 5. Takeuchi M, Makita Z. Alternative routes for the formation of immunochemically distinct advanced glycation end-products in vivo. Curr Mol Med. 2001;1: 305–315. pmid:11899079
- 6. Goldberg T, Cai W, Peppa M, Dardaine V, Baliga BS, Uribarri J, et al. Advanced glycoxidation end products in commonly consumed foods. J Am Diet Assoc. 2004;104: 1287–1291. pmid:15281050
- 7. Uribarri J, Woodruff S, Goodman S, Cai W, Chen X, Pyzik R, et al. Advanced glycation end products in foods and a practical guide to their reduction in the diet. J Am Diet Assoc. 2010 110: 911–916. pmid:20497781
- 8. Poulsen MW, Hedegaard RV, Andersen JM, de Courten B, Bugel S, Nielsen J, et al. Advanced glycation end products in food and their effects on health. Food Chem Toxicol. 2013;60: 10–37. pmid:23867544
- 9. Sebekova K, Somoza V. Dietary advanced glycation endproducts (AGEs) and their health effects—PRO. Mol Nutr Food Res. 2007;51: 1079–1084. pmid:17854003
- 10. Uribarri J, Cai W, Peppa M, Goodman S, Ferrucci L, Striker G, et al. Circulating glycotoxins and dietary advanced glycation endproducts: two links to inflammatory response oxidative stress, and aging. J Gerontol A Biol Sci Med Sci. 2007;62: 427–433. pmid:17452738
- 11. Semba RD, Ang A, Talegawkar S, Crasto C, Dalal M, Jardack P, et al. Dietary intake associated with serum versus urinary carboxymethyl-lysine, a major advanced glycation end product, in adults: the Energetics Study. Eur J Clin Nutr. 2012;66: 3–9. pmid:21792213
- 12. Alamir I, Niquet-Leridon C, Jacolot P, Rodriguez C, Orosco M, Anton PM, et al. Digestibility of extruded proteins and metabolic transit of N-ε-carboxymethyllysine in rats. Amino Acids. 2013;44: 1441–1449. pmid:23160731
- 13. Takeuchi M, Makita Z, Yanagisawa K, Kameda Y, Koike T. Detection of noncarboxymethyllysine and carboxymethyllysine advanced glycation end products (AGE) in serum of diabetic patients. Mol Med. 1999;5: 393–405. pmid:10415164
- 14. Takeuchi M, Makita Z, Bucala R, Suzuki T, Koike T, Kameda Y. Immunological evidence that non-carboxymethyllysine advanced glycation end-products are produced from short chain sugars and dicarbonyl compounds in vivo. Mol Med. 2000;6: 114–125. pmid:10859028
- 15. Takeuchi M, Yanase Y, Matsuura N, Yamagishi S, Kameda Y, Bucala R, et al. Immunological detection of a novel advanced glycation end-product. Mol Med. 2001;7: 783–791. pmid:11788793
- 16. Takeuchi M, Iwaki M, Takino J, Shirai H, Kawakami M, Bucala R, et al. Immunological detection of fructose-derived advanced glycation end-products. Lab Invest. 2010;90: 1117–1127. pmid:20212455
- 17. Takeuchi M, Yamagishi S. TAGE (toxic AGEs) hypothesis in various chronic diseases. Med Hypotheses. 2004;63: 449–452. pmid:15288366
- 18. Takeuchi M, Yamagishi S. Involvement of toxic AGEs (TAGE) in the pathogenesis of diabetic vascular complications and Alzheimer’s disease. J Alzheimers Dis. 2009;16: 845–858. pmid:19387117
- 19. Takeuchi M, Takino J, Yamagishi S. Involvement of the toxic AGEs (TAGE)-RAGE system in the pathogenesis of diabetic vascular complications: A novel therapeutic strategy. Curr Drug Targets. 2010;11: 1468–1482. pmid:20583971
- 20. Sato T, Wu X, Shimogaito N, Takino J, Yamagishi S, Takeuchi M. Effects of high-AGE beverage on RAGE and VEGF expressions in the liver and kidneys. Eur J Nutr. 2009;48: 6–11. pmid:19083041
- 21. Tsunosue M, Makiko N, Ohta Y, Matsuo Y, Ueda K, Ninomiya M, et al. An α-glucosidase inhibitor, acarbose treatment decreases serum levels of glyceraldehyde-derived advanced glycation end products (AGEs) in patients with type 2 diabetes. Clin Exp Med. 2010;10: 139–141. pmid:19834782
- 22. Tahara N, Yamagishi S, Matsui T, Takeuchi M, Nitta Y, Kodama N, et al. Serum levels of advanced glycation end products (AGEs) are independent correlates of insulin resistance in non-diabetic subjects. Cardiovasc Ther. 2012;30: 42–48. pmid:20626403
- 23. Tahara N, Yamagishi S, Takeuchi M, Honda A, Tahara A, Nitta Y, et al. Positive association between serum level of glyceraldehyde-derived advanced glycation end products (AGEs) and vascular inflammation evaluated by 18F-fluorodeoxyglucose positron emission tomography (FDG-PET). Diabetes Care. 2012;35: 2618–2625. pmid:22912424
- 24. Ueda S, Yamagishi S, Matsui T, Noda Y, Ueda SI, Jinnouchi Y, et al. Serum levels of advanced glycation end products (AGEs) are inversely associated with the number and migratory activity of circulating endothelial progenitor cells in apparently healthy subjects. Cardiovasc Ther. 2012;30: 249–254. pmid:21884000
- 25. Fukushima Y, Daida H, Morimoto T, Kasai T, Miyauchi K, Yamagishi SI, et al. Relationship between advanced glycation end products and plaque progression in patients with acute coronary syndrome: The JAPAN-ACS Sub-study. Cardiovasc Diabetol. 2013;12: 5. Available: http://www.cardiab.com/content/12/1/5. pmid:23289728
- 26. Ueda S, Yamagishi S, Takeuchi M, Kohno K, Shibata R, Matsumoto Y, et al. Oral adsorbent AST-120 decreases serum levels of AGEs in patients with chronic renal failure. Mol Med. 2006;12: 180–184. pmid:17088950
- 27. Yamagishi S, Inagaki Y, Okamoto T, Amano S, Koga K, Takeuchi M, et al. Advanced glycation end product-induced apoptosis and overexpression of vascular endothelial growth factor and monocyte chemoattractant protein-1 in human-cultured mesangial cells. J Biol Chem. 2002;277: 20309–20315. pmid:11912219
- 28. Vlassara H, Striker GE. AGE restriction in diabetes mellitus: a paradigm shift. Nat Rev Endocrinol. 2011;7: 526–539. pmid:21610689
- 29. Semba RD, Gebauer SK, Baer DJ, Sun K, Turner R, Silber HA, et al. Dietary intake of advanced glycation end products did not affect endothelial function and inflammation in healthy adults in a randomized controlled trial. J Nutr. 2014;44: 1037–1042.
- 30. Kellow NJ, Savige GS. Dietary advanced glycation end-product restriction for the attenuation of insulin resistance, oxidative stress and endothelial dysfunction: a systematic review. Eur J Clin Nutr. 2013;67: 239–248. pmid:23361161
- 31. Henle T. Protein-bound advanced glycation endproducts (AGEs) as bioactive amino acid derivatives in foods. Amino Acids. 2005;29: 313–322. pmid:15997413
- 32. Zhang Q, Ames JM, Smith RD, Baynes JW, Metz TO. A perspective on the Maillard reaction and the analysis of protein glycation by mass spectrometry: probing the pathogenesis of chronic disease. J Proteome Res. 2009;8: 754–769. pmid:19093874
- 33. Assar S, Moloney C, Lima M, Magee R, Ames J. Determination of Nε-(carboxymethyl)lysine in food systems by ultra performance liquid chromatography-mass spectrometry. Amino Acids. 2009;36: 317–326. pmid:18389168
- 34. Schalkwijk CG, Stehouwer CD, van Hinsbergh VW. Fructose-mediated non-enzymatic glycation: sweet coupling or bad modification. Diabetes Metab Res Rev. 2004;20: 369–382. pmid:15343583
- 35. Ahmed N, Argirov OK, Minhas HS, Cordeiro CA, Thornalley PJ. Assay of advanced glycation endproducts (AGEs): surveying AGEs by chromatographic assay with derivatization by 6-aminoquinolyl-N-hydroxysuccinimidylcarbamate and application to N-epsilon-carboxymethyl-lysine- and Nepsilon-(1-carboxyethyl)lysine-modified albumin. Biochem J. 2002;364: 1–14. pmid:11988070
- 36. Ahmed N, Mirshekar-Syahkal B, Kennish L, Karachalias N, Babaei-Jadidi R, Thornally PJ. Assay of advanced glycation endproducts in selected beverages and food by liquid chromatography with tandem mass spectrometric detection. Mol Nutr Food Res. 2005;49: 691–699. pmid:15945118
- 37. Koschinsky T, He CL, Mitsuhashi T, Bucala R, Liu C, Buenting C, et al. Orally absorbed reactive glycation products (glycotoxins): an environmental risk factor in diabetic nephropathy. Proc Natl Acad Sci USA. 1997;94: 6474–6479. pmid:9177242
- 38. Makita Z, Vlassara H, Cerami A, Bucala R. Immunochemical detection of advanced glycosylation end products in vivo. J Biol Chem. 1992;267: 5133–5138. pmid:1371995